QuidelOrtho Corporation
QDEL Healthcare Medical Devices
QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024. In the quarter to June 2026, revenue grew 2.77%, EPS grew 63.9%, free cash flow fell 61.5% and total debt rose 10.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow QDEL
QuidelOrtho Corporation (QDEL) EV/Sales
As of 16 October 2026, QuidelOrtho Corporation (QDEL) trades at a EV/Sales of 1.4×. Over the past ten years it has ranged from 1.1× (May 2022) to 19.5× (August 2020); the current reading is higher than 5% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | (16.30%) |
| FY2024 | 1.9× | (19.97%) |
| FY2023 | 2.4× | 10.75% |
| FY2022 | 2.2× | (23.72%) |
| FY2021 | 2.9× | (33.91%) |
| FY2020 | 4.3× | (26.12%) |
| FY2019 | 5.9× | 63.37% |
| FY2018 | 3.6× | (46.50%) |
| FY2017 | 6.7× | 95.09% |
| FY2016 | 3.4× | (0.81%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 7.39% |
| Mar 2026 | 1.4× | (14.67%) |
| Dec 2025 | 1.6× | (3.78%) |
| Sep 2025 | 1.7× | 4.62% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AHCO AdaptHealth Corp. compare | 0.8× |
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| QDEL QuidelOrtho Corporation | 1.4× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.5× |
| AORT Artivion, Inc. compare | 2.9× |
| SIBN SiBone compare | 3.6× |
| BBNX Beta Bionics, Inc. compare | 4.6× |
| CBLL CeriBell, Inc. compare | 8.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)